Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Repare Therapeutics ( (RPTX) ) is now available.
On December 18, 2025, Repare Therapeutics announced that Chief Scientific Officer Michael Zinda, Ph.D., had resigned effective December 31, 2025, and entered into a separation agreement that provides nine months of salary, a retention payment, a 2025 target bonus, extended COBRA health coverage, accelerated vesting of certain equity awards, and an extended exercise window for vested stock options, alongside a three-month consulting arrangement at an hourly rate. The agreement also outlines enhanced change-in-control separation benefits that would replace the standard package if the planned acquisition of Repare by XenoTherapeutics or another qualifying change in control occurs on or shortly after his departure, underscoring both the company’s ongoing M&A process and the effort to manage executive transition and retention as shareholders prepare to vote on the Xeno deal at a special meeting on January 16, 2026.
The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
Repare Therapeutics’ overall stock score is driven by positive technical indicators and promising corporate developments, despite financial challenges and poor valuation metrics. The company’s strong cash position and recent trial data provide a foundation for potential future improvements.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics Inc. is a biopharmaceutical company focused on developing precision oncology therapies, leveraging synthetic lethality and other targeted approaches to treat cancers with specific genetic profiles.
Average Trading Volume: 557,699
Technical Sentiment Signal: Hold
Current Market Cap: $94.41M
Learn more about RPTX stock on TipRanks’ Stock Analysis page.